Cargando…
Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 M(pro))
The COVID-19 pandemic caused by SARS-CoV-2 continues to pose a great threat to public health while various vaccines are available worldwide. Main protease (M(pro)) has been validated as an effective anti-COVID-19 drug target. Using medicinal chemistry and rational drug design strategies, we identifi...
Autores principales: | Zhang, Kuojun, Wang, Tianyu, Li, Maotian, Liu, Mu, Tang, He, Wang, Lin, Ye, Ke, Yang, Jiamei, Jiang, Sheng, Xiao, Yibei, Xie, Youhua, Lu, Meiling, Zhang, Xiangyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205138/ https://www.ncbi.nlm.nih.gov/pubmed/37257212 http://dx.doi.org/10.1016/j.ejmech.2023.115487 |
Ejemplares similares
-
Discovery of 4′-O-methylscutellarein as a potent SARS-CoV-2 main protease inhibitor
por: Wu, Qianqian, et al.
Publicado: (2022) -
Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection
por: Ge, Rui, et al.
Publicado: (2022) -
Novel covalent and non-covalent complex-based pharmacophore models of SARS-CoV-2 main protease (M(pro)) elucidated by microsecond MD simulations
por: Hayek-Orduz, Yasser, et al.
Publicado: (2022) -
Supercomputer simulation of the covalent inhibition of the main protease of SARS-CoV-2
por: Nemukhin, A. V., et al.
Publicado: (2022) -
Alkyne as a
Latent Warhead to Covalently Target SARS-CoV-2
Main Protease
por: Ngo, Chau, et al.
Publicado: (2023)